the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Clinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates
with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn
(TTN).
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Warsaw
Collaborators:
Jagiellonian University Jan Biziel University Hospital No 2 in Bydgoszcz Neonatology Unit, Specialist Hospital No 2, Bytom Pomeranian Medical University Szczecin Poznan University of Medical Sciences University in Zielona Góra University of Ottawa University of Rzeszow